肺高血圧症治療薬の世界市場2015-2019

【英語タイトル】Pulmonary Hypertension - Global Market Research 2015-2019

Technavioが出版した調査資料(IRTNTR7554)・商品コード:IRTNTR7554
・発行会社(調査会社):Technavio
・発行日:2015年9月30日
・ページ数:65
・レポート言語:英語
・レポート形式:pdf
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥339,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、肺高血圧症治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、肺高血圧症治療薬の世界市場規模及び予測、種類別分析、作用機序別分析、市場シェア、地域別分析、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。
【レポートの概要】

About pulmonary hypertension
Pulmonary hypertension is a rare disorder that affects the pulmonary arteries carrying deoxygenated blood to the lungs from the heart. The narrowing or blockage of pulmonary arteries will lead to pulmonary hypertension. Symptoms of the disease do not occur until the disease becomes severe. Certain causes of pulmonary hypertension include emphysema, connective tissue disorders, blood clots in lungs, and sleep apnea. Pulmonary hypertension may sometimes lead to several chronic illnesses, such as kidney failure (renal failure), heart failure, aneurysm, heart attack, or, stroke. Endothelin receptor antagonists, prostacyclin analogs, phosphodiesterase inhibitors, and sGC stimulators are popular drug therapeutic classes available for the treatment of pulmonary hypertension.

Technavio’s analysts forecast the global pulmonary hypertension market to grow at a CAGR of 2.92% over the period 2014-2019.

[Covered in this report]
The report includes the present scenario and the growth prospects of the global pulmonary hypertension market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used in the treatment of pulmonary hypertension.

Technavio’s report, Global Pulmonary Hypertension Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation and pipeline landscape. The report includes a discussion of the key vendors operating in this market.

[Key vendors]
• Actelion
• Bayer
• GlaxoSmithKline
• United Therapeutics

[Other prominent vendors]
• Aires Pharmaceuticals
• Arena Pharmaceuticals
• Bial
• DEKA
• Dong-A ST
• Gilead
• Merck
• Northern Therapeutics
• Novartis
• Pfizer
• PhaseBio

[Market Driver]
• Growing incidence of pulmonary hypertension
• For a full, detailed list, view our report

[Market challenge]
• Patent expiry
• For a full, detailed list, view our report

[Market trend]
• Increased focus on combination therapies
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【レポートの目次】

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 06: Pipeline portfolio
Key information of pipeline candidates

PART 07: Market segmentation by type of formulation
Oral
Injection
Inhalation

PART 08: Market segmentation by mechanism of action
Endothelin receptor antagonist
Prostacyclin analogs
Phosphodiesterase inhibitors
Soluble guanylate cyclase stimulators

PART 09: Geographical segmentation

PART 10: Market drivers
Increase in incidence of pulmonary hypertension
Patient assistance programs
New disease-modifying therapies
Unmet medical needs

PART 11: Impact of drivers

PART 12: Market challenges
Patent expiry
Poor patient compliance
Intense competition among vendors

PART 13: Impact of drivers and challenges

PART 14: Market trends
Increased focus on combination therapies
Increase in awareness of hypertension
Strategic alliances

PART 15: Vendor landscape
Competitive scenario
Key news
Mergers and acquisitions
Market share analysis 2014
Other prominent vendors

PART 16: Key vendor analysis
Actelion Pharmaceuticals
Bayer HealthCare
GSK
United Therapeutics

PART 17: Appendix
List of abbreviations

PART 18: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Global pulmonary hypertension market: 2014-2019 ($ billions)
Exhibit 03: Five forces analysis
Exhibit 04: Pipeline portfolio
Exhibit 05: Market segmentation by type of formulation
Exhibit 06: Market segmentation by type of formulation 2014
Exhibit 07: Market segmentation by mechanism of action
Exhibit 08: Market segmentation by mechanism of action 2014
Exhibit 09: Market segmentation by region 2014
Exhibit 10: Impact of drivers
Exhibit 11: Revatio sales in the US 2011-2014 ($ millions)
Exhibit 12: Impact of drivers and challenges
Exhibit 13: Actelion Pharmaceuticals : Key takeaways
Exhibit 14: Tracleer: Global sales 2011-2014 ($ billions)
Exhibit 15: Opsumit: Global sales 2013-2015 H1 ($ millions)
Exhibit 16: Ventavis: Global sales 2011-2014 ($ millions)
Exhibit 17: Veletri: Global sales 2011-2014 ($ millions)
Exhibit 18: United Therapeutics: Key takeaways
Exhibit 19: Remodulin: Global sales 2011-2014 ($ millions)
Exhibit 20: Tyvaso: Global sales 2011-2014 ($ millions)
Exhibit 21: Adcirca: Global sales 2011-2014 ($ millions)
Exhibit 22: Orenitram: Global sales 2014-2015 H2 ($ millions)
Exhibit 23: GlaxoSmithKline: Key takeaways
Exhibit 24: Flolan: Global sales 2012-2013 ($ millions)
Exhibit 25: Bayer: Key takeaways
Exhibit 26: Adempas: Global sales 2013-2014 ($ millions)
Exhibit 27: Actelion Pharmaceuticals: Product segmentation
Exhibit 28: Actelion Pharmaceuticals: Business segmentation by revenue 2014
Exhibit 29: Actelion Pharmaceuticals: Business segmentation by revenue 2013 and 2014 ($ millions)
Exhibit 30: Actelion Pharmaceuticals: Geographical segmentation by revenue 2014
Exhibit 31: United Therapeutics: Product segmentation by revenue 2014
Exhibit 32: United Therapeutics: Product segmentation by revenue 2014 ($ millions)
Exhibit 33: United Therapeutics: Geographical segmentation by revenue 2014



【掲載企業】

Actelion, Bayer, GlaxoSmithKline, United Therapeutics, Aires Pharmaceuticals, Arena Pharmaceuticals, Bial, DEKA, Dong-A ST, Gilead, Merck, Northern Therapeutics, Novartis, Pfizer, PhaseBio, Radikal Therapeutics, Reata Pharmaceuticals, SteadyMed.

【レポートのキーワード】

肺高血圧症、肺高血圧症治療薬、肺、医薬品、パイプライン、製薬

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[肺高血圧症治療薬の世界市場2015-2019] (コード:IRTNTR7554)販売に関する免責事項を必ずご確認ください。
★調査レポート[肺高血圧症治療薬の世界市場2015-2019]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆